Watch this Wall Street Journal interview on why Dr. Wischik sees tau as a more worthwhile anti-Alzheimer's target than plaque. Learn more about TauRx' Alzheimer's trial drug called Rember.
Read more »
Sunday, November 18, 2012
WSJ: Rember Tackles the Tau behind Alzheimer's
Labels:
Clinical Trials •
Research
Watch this Wall Street Journal interview on why Dr. Wischik sees tau as a more worthwhile anti-Alzheimer's target than plaque. Learn more about TauRx' Alzheimer's trial drug called Rember.
Read more »
